ReviewCirculation research2010
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Review in Circulation research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 161 citations in OpenAlex.
- Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial.Open heart · 2026Trial
- Non-Fasting Glucose Measures and Their Clinical Significance in Diabetes Diagnosis and Cardiovascular and Cancer Risk Prediction: A Narrative Review.International journal of molecular sciences · 2026Review
- Metabolic and biochemical profiling reveals phenotypic heterogeneity in Zucker diabetic fatty rats.Animal models and experimental medicine · 2026Article
- Microbial Metabolite, Macro Impact: Urolithin A in the Nexus of Insulin Resistance and Colorectal Tumorigenesis.Nutrients · 2025Review
- Taurine in Type 2 Diabetes: Plasma Concentrations, Metabolic Pathways, and Potential as a Therapeutic Adjuvant.Current nutrition reports · 2025Review
- Effects of High Glucose on Simulated Ischemia/Reperfusion Injury in Isolated Cardiomyocytes.International journal of molecular sciences · 2025Article
- Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts.American journal of physiology. Heart and circulatory physiology · 2025Article
- Aldose reductase, fructose and fat production in the liver.The Biochemical journal · 2025Review
- The effect of consuming bread contaminated with heavy metals on cardiovascular disease and calculating its risk assessment.Scientific reports · 2025Article
- Glucose metabolic dysregulation of diabetes and Its role in atrial fibrillation pathogenesis.Frontiers in cardiovascular medicine · 2025Review
- Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial.Heart failure reviews · 2024Review
- Ferroptosis-A Shared Mechanism for Parkinson's Disease and Type 2 Diabetes.International journal of molecular sciences · 2024Review
- The relationship of redox signaling with the risk for atherosclerosis.Frontiers in pharmacology · 2024Review
- Applying Network Pharmacology and Molecular Docking in the Screening for Molecular Mechanisms of Ampalaya (Acta medica Philippina · 2024Article
- The Role of Aldose Reductase in Polyol Pathway: An Emerging Pharmacological Target in Diabetic Complications and Associated Morbidities.Current pharmaceutical biotechnology · 2024Review
- The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence.Frontiers in aging · 2024Article
- Aquaporins contribute to vacuoles formation in Nile grass type II diabetic rats.Medical molecular morphology · 2023Article
- Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.Journal of translational medicine · 2023Article
- Advanced polymer hydrogels that promote diabetic ulcer healing: mechanisms, classifications, and medical applications.Biomaterials research · 2023Review
- Translating the advanced glycation end products (AGEs) knowledge into real-world nutrition strategies.European journal of clinical nutrition · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Hyperglycemia and reduced insulin actions affect many biological processes. One theory is that aberrant metabolism of glucose via several pathways including the polyol pathway causes cellular toxicity. Aldose reductase (AR) is a multifunctional enzyme that reduces aldehydes. Under diabetic conditions AR converts glucose into sorbitol, which is then converted to fructose. This article reviews the biology and pathobiology of AR actions. AR expression varies considerably among species. In humans and rats, the higher level of AR expression is associated with toxicity. Flux via AR is increased by ischemia and its inhibition during ischemia reperfusion reduces injury. However, similar pharmacological effects are not observed in mice unless they express a human AR transgene. This is because mice have much lower levels of AR expression, probably insufficient to generate toxic byproducts. Human AR expression in LDL receptor knockout mice exacerbates vascular disease, but only under diabetic conditions. In contrast, a recent report suggests that genetic ablation of AR increased atherosclerosis and increased hydroxynonenal in arteries. It was hypothesized that AR knockout prevented reduction of toxic aldehydes. Like many in vivo effects found in genetically manipulated animals, interpretation requires the reproduction of human-like physiology. For AR, this will require tissue specific expression of AR in sites and at levels that approximate those in humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.